2025 NMD4C Basic Research Summer School to be Held at York University
Update: Applications are now open! We are thrilled to announce that we will be hosting our second annual basic research summer school for neuromuscular research trainees over May 7-8, 2025 at York University in Toronto, ON.
2025 Summer School Themes
The second edition of the NMD4C summer school will be led by Dr. Chris Perry, and will focus on two key themes over the two days:
- Fibre Isolation and Analysis (led by Dr Anthony Scimè)
- Rodent Muscle Function Assessment (led by Dr Arthur Cheng).
The NMD4C summer school provides lecture-based and hands-on training workshops to neuromuscular trainees in cutting-edge wet lab techniques, while providing an environment for trainees to present their research and network in-person with colleagues and senior investigators from across Canada.
The 2025 NMD4C Summer School will take place in the days before the York University Muscle Health Research Centre’s Muscle Health Awareness Day, an annual event that brings together researchers and students who study muscle health in a multitude of experimental paradigms, and provides an opportunity for the presentation of their research.
Supporting preclinical trainees and scientists is a key focus of the network, and we are aiming to make this event as accessible as possible for trainees to attend from across Canada. There will be no registration fee and support will be available for accommodation in Toronto and for travel.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.